EBO2 gently “tunes up” the blood and circulation before any plasma is removed. It helps the body’s own defenses work better and reduces inflammation. Plasmapheresis then acts like a blood “filter and refill,” removing harmful antibodies and inflammatory proteins while returning the blood cells in a clean replacement fluid. Together, the first step prepares the system, and the second step clears out what’s left
Overview
Extracorporeal Blood Oxygenation and Ozonation (EBO2) and therapeutic plasma exchange (TPE, plasmapheresis) are often discussed as competing extracorporeal strategies, yet mechanistically, they may be more rationally viewed as complementary, sequential interventions. EBO2 can be conceptualized as a high-volume recirculatory blood oxygenation–ozonation–filtration procedure, whereas TPE is a plasma-removal-and-replacement therapy designed to reduce pathogenic plasma constituents, including autoantibodies, immune complexes, inflammatory cytokines, complement components, and selected lipoproteins and extracellular vesicles.
A plausible sequencing model is to use EBO2 first as a redox-signaling intervention, followed a few days later by TPE as a more decisive “plasma reset.” In simple terms, EBO2 may “prepare the terrain” by shifting oxidative stress, inflammatory transcriptional programs, and microcirculatory function. Plasmapheresis then removes a substantial fraction of the remaining pathogenic plasma factors that sustain disease.
This article outlines the rationale in a scientifically grounded yet accessible way. It does not claim that this sequence has been proven superior across indications in large, randomized trials. Rather, it integrates mechanistic and clinical evidence from the ozone therapy and TPE literature to explain why an “EBO2-then-TPE” sequence may be appealing for many chronic inflammatory and immune-mediated conditions.
Biological Actions of EBO2
EBO₂ gently stresses the blood in a controlled way, prompting the body to activate its own protective systems. This activates antioxidant and repair pathways, calms down inflammatory switches, and improves blood flow in small vessels. Together, these changes help the body better handle ongoing inflammation and oxidative stress.
EBO2 exposes circulating blood to a medical oxygen–ozone mixture extracorporeally as it passes through a dialyzer membrane. The central biological concept behind medical ozone is not indiscriminate oxidation but a controlled, low-dose oxidative stimulus that generates short-lived reactive oxygen species (ROS), also known as free radicals, and a family of lipid oxidation products (LOPs) that act as second messengers in redox signaling.
At appropriate doses, this mild oxidative challenge triggers hormesis: a small stress that stimulates the upregulation of endogenous defense and repair systems. Multiple experimental and early clinical studies show that ozone exposure can activate antioxidant pathways, improve the antioxidant–prooxidant balance, and reduce markers of oxidative damage and stress.
Many chronic diseases are marked by persistent oxidative stress, depleted antioxidant reserves, endothelial dysfunction, mitochondrial distress, and a pro-inflammatory plasma milieu. By engaging redox-sensitive transcription factors and stress-response networks, EBO2 may help restore a more resilient redox and vascular environment, thereby improving tolerance and potentially increasing the effectiveness of a subsequent plasma-removal procedure.
Pathways Modulated by EBO2
Nrf2 and the antioxidant response
Nuclear factor erythroid 2–related factor 2 (Nrf2) orchestrates the expression of a broad array of antioxidant and phase II detoxification genes. Reviews of ozone biology and specific experimental studies indicate that ozone-generated ROS and LOPs can activate Nrf2, leading to upregulation of superoxide dismutase (SOD), catalase, glutathione peroxidase, glutathione S-transferases, NAD(P)H: quinone oxidoreductase-1 (NQO1), and heme oxygenase-1 (HO-1).
These compounds are natural protective enzymes that help cells reduce harmful oxidants and remove toxic by-products.
For example, Bocci and colleagues demonstrated that ozonation of human blood ex vivo induces a “remarkable” antioxidant response, including HO-1 induction, which protects against vascular constriction and oxidative injury. In multiple sclerosis and other inflammatory models, systemic ozone therapy has been shown to enhance antioxidant enzyme activity and increase intracellular reduced glutathione levels, consistent with activation of the Nrf2 pathway.
For clinicians, this can be explained simply: EBO2 does not just remove “bad” molecules; it appears to switch on the body’s own antioxidant defense programs, improving internal housekeeping before more aggressive plasma subtraction is undertaken.
NF-κB and cytokine modulation
Nrf2 and NF-κB are two major regulatory switches for cellular stress and inflammation. When Nrf2 is activated, it usually attenuates NF-κB–driven inflammatory signals. Ozone therapy can dampen NF-κB activity and lower key inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IL-17 in multiple inflammation models.”
In psoriasis models, for instance, topical ozone reduced NF-κB activation and attenuated local inflammatory reactions and Th17 cell activity. In broader mechanistic reviews, ozone-induced NRF2 activation is linked to inhibition of NF-κB and reduced expression of NF-κB–dependent inflammatory cytokines.
Translating this to EBO2, the procedure may not only enhance antioxidant defenses but also lower the “volume knob” on inflammatory transcription, thereby creating a quieter cytokine environment before TPE is used to bulk remove these mediators from the plasma compartment.
AMPK, FOXO, mTOR, Sirt1, and metabolic stress signaling
In addition to Nrf2, ozone appears to engage broader stress-response pathways, including AMPK, FOXO transcription factors, mTOR, and Sirt1. These networks govern mitochondrial stress responses, autophagy, cellular energy sensing, and survival under metabolic strain.
A 2022 Frontiers in Microbiology review of ozone therapy for emerging viral diseases describes ozone-induced modulation of AMPK/FOXO/mTOR/Sirt1 signaling as part of a coordinated adaptive response that promotes mitochondrial resilience and anti-inflammatory effects. The available ozone literature supports the view that mild ROS signaling can nudge cells toward a more energy-efficient, stress-resilient phenotype.
The clinical relevance is that EBO2 may help reprogram cellular metabolism and stress resilience before TPE subtracts circulating drivers; together, this could address both the “software” (signaling) and “hardware” (plasma contents) aspects of disease biology.
NLRP3 inflammasome
The NLRP3 inflammasome is an immune ‘alarm system’ that activates IL-1β and IL-18, thereby amplifying inflammation. Ozone therapy can dial down this alarm in some models, lowering inflammasome-driven cytokine release. If the same happens during EBO2, reducing NLRP3 activity early could slow the inflammatory surge before cytokines rise in the blood. For clinicians, this means EBO2 may act on both early trigger pathways and later cytokine signals, while plasmapheresis helps clear the remaining inflammatory ‘debris’ from plasma.
HO-1, nitric oxide, and microcirculation
HO-1 induction is a recurring finding in ozonated blood studies and is central to the vascular effects of ozone. HO-1 degrades heme to biliverdin, free iron, and carbon monoxide, with antioxidant, anti-apoptotic, and vasodilatory actions. Research suggests that ozone-induced HO-1 expression in vascular cells may protect against abnormal vasoconstriction and smooth muscle proliferation.
In parallel, ozone and its LOPs can influence nitric oxide (NO) signaling and erythrocyte deformability, improving microcirculatory flow and tissue oxygen delivery in some models. For EBO2, these vascular and rheologic effects may stabilize and optimize microcirculation before a more hemodynamically demanding plasma-exchange procedure.
Mechanistic Overview of Therapeutic Plasma Exchange
Therapeutic plasma exchange (TPE) takes blood from a vein, separates out the liquid part (plasma), and removes harmful antibodies, inflammatory proteins, fats, and toxins. The blood cells are mixed with clean replacement fluid and returned to the body. This ‘plasma reset’ can quickly calm immune reactions, improve blood thickness and flow, and ease symptoms in conditions driven by bad proteins circulating in the blood.
TPE is a well-established extracorporeal blood purification technique in which plasma is separated from cellular components and replaced with albumin, saline, or donor plasma. The primary clinical intent is to reduce the levels of circulating pathologic plasma components, including autoantibodies, immune complexes, complement factors, paraproteins, cryoglobulins, lipoproteins, inflammatory cytokines, and selected toxins.
Modern reviews estimate that exchanging 1 plasma volume removes roughly 60–70% of intravascular IgG and similarly sized proteins; exchanging 1.5–2 plasma volumes can achieve even greater removal, though at the expense of greater exposure to replacement fluids. Mechanistically, TPE not only depletes harmful antibodies and immune complexes but also alters the broader immune milieu—modifying cytokine profiles, complement activity, and soluble receptor levels.
Clinically, TPE is a guideline-supported first-line therapy for multiple antibody-mediated and hyperviscosity conditions, including Guillain-Barré syndrome, myasthenia gravis crisis, thrombotic thrombocytopenic purpura, anti-GBM disease, and catastrophic antiphospholipid syndrome, among others. However, by design, it is a subtractive therapy: it removes both harmful and potentially beneficial plasma proteins and does not directly induce the hormetic redox and adaptive stress responses observed with ozone-based therapies.
Rationale for Performing EBO2 Before Plasmapheresis
From a systems-biology perspective, a coherent argument can be made for sequencing EBO2 before TPE:
- Priming cellular defenses. EBO2 may activate Nrf2-centered antioxidant programs, HO-1 expression, and broader AMPK/FOXO/mTOR/Sirt1 stress responses, while attenuating NF-κB and NLRP3 inflammasome signaling, thereby reducing oxidative stress and inflammatory drive.
- Improving vascular and rheologic conditions. By modulating NO signaling, HO-1 activity, and erythrocyte deformability, EBO2 may improve microcirculatory flow and tissue oxygenation, thereby enhancing tolerance to subsequent plasma exchange.
- Lowering inflammatory “noise.” Once upstream signaling is partially normalized, the residual plasma burden of antibodies, immune complexes, lipoproteins, and cytokines becomes a more defined target for TPE to remove.
- Reducing resource intensity per benefit. In theory, by first reducing inflammatory drive and oxidative stress, fewer or less intense TPE sessions might be needed to achieve a given clinical effect, although this remains to be demonstrated formally.
In contrast, starting with TPE alone clears the plasma compartment but leaves underlying redox and cellular signaling abnormalities largely unaddressed. The system may remain prone to rapid “refilling” of pathogenic mediators if the inflammatory and metabolic context is not improved.
Why a Gap of a Few Days Is Biologically Plausible
The rationale for spacing EBO2 and TPE by a few days arises from the temporal dynamics of their mechanisms. Ozone-induced responses Nrf2 activation, HO-1 induction, antioxidant enzyme upregulation, and immunometabolic recalibration are fundamentally transcriptional and post-translational processes that evolve over hours to days rather than minutes.
Allowing a short “adaptation window” after EBO2 gives these protective programs time to consolidate. Clinically, this period also allows the physician to assess tolerance, monitor laboratory markers, and adjust hydration and anticoagulation parameters before the patient is exposed to the volume shifts and replacement fluid loads associated with TPE.
Because TPE removes both harmful and beneficial proteins, performing it immediately after EBO2 could potentially wash out early adaptive changes in the plasma milieu before they have significantly influenced downstream cellular behavior. A short delay of a few days may mitigate this concern, although this remains a hypothesis that would benefit from focused translational studies.
A Stepwise Biological Model
A stepwise conceptual model for an “EBO2-first” sequence is:
- EBO2 phase (signaling and conditioning).
Controlled oxidative and filtration-based exposure generates ROS and LOPs, activating Nrf2 and related transcriptional programs, attenuating NF-κB and NLRP3 activity, and inducing HO-1 and other cytoprotective proteins, with beneficial effects on oxidative stress, inflammation, and microcirculation. - Over the subsequent days, antioxidant and anti-inflammatory gene programs consolidate; mitochondrial and metabolic signaling adapt; and the clinical picture is reassessed to determine trajectory and readiness for TPE.
- Plasmapheresis phase (subtraction).
One or more TPE sessions are performed to remove residual pathogenic plasma factors, including autoantibodies, immune complexes, complement, lipoproteins, and inflammatory cytokines, by leveraging a system that has already been partially de-inflamed and redox-conditioned. - Combined effect (reprogram and clean-up).
The combination provides both biological “reprogramming” via EBO2-induced signaling and physical “clean-up” via TPE-mediated subtraction, potentially offering a broader therapeutic impact than either approach alone.
For lay communication, EBO2 can be likened to stabilizing and updating the system’s software, while plasmapheresis is more akin to flushing and replacing contaminated fluid in the hardware.
Where This Sequence May Be Most Relevant
The EBO2-then-TPE sequence is most conceptually attractive in non-acute settings where disease biology clearly involves both dysregulated cellular signaling and a persistent pathogenic plasma milieu. Examples include:
- Chronic inflammatory and immune-activation syndromes where oxidative stress and cytokine excess coexist.
- Post-infectious or post-viral conditions (including some post-COVID-19 phenotypes) where a pro-inflammatory immune milieu and autoantibodies are implicated, and TPE has shown promise in clearing soluble inflammatory mediators.
- Metabolic–vascular dysfunction and cardiometabolic aging phenotypes, where microcirculatory impairment, endothelial dysfunction, and pro-inflammatory lipoprotein profiles coexist.
- Selected toxin or biotoxin exposures, where both redox conditioning and removal of circulating toxic complexes may be desirable.
- General wellbeing
By contrast, in acute, guideline-driven indications such as myasthenic crisis, thrombotic thrombocytopenic purpura, anti-GBM disease, and catastrophic antiphospholipid syndrome, the immediate therapeutic priority is rapid removal of pathogenic plasma components. In these scenarios, conventional recommendations still favor early TPE, and there is little rationale for delaying TPE to perform EBO2 first.
Clinical Interpretation
A scientifically cautious interpretation is that EBO2 may be best considered a priming intervention when the therapeutic goal is not only to remove harmful plasma components but also to activate endogenous protective pathways and normalize redox and inflammatory signaling before a subsequent plasma exchange. In this conceptual framework, EBO2 conditions the host, and TPE then clears residual circulating drivers.
At the pathway level, this sequence is coherent: EBO2 can stimulate Nrf2-centered antioxidant defense, induce HO-1, modulate AMPK/FOXO/mTOR/Sirt1 stress responses, attenuate NF-κB and NLRP3 inflammatory signaling, and improve microcirculatory dynamics. TPE performed a few days later can then remove residual antibodies, immune complexes, cytokines, lipoproteins, and other soluble mediators that perpetuate pathology.
In short, the rationale is not merely to “stack” two complex interventions, but to use the first to improve the internal biologic state and the second to reduce the remaining plasma burden within a cleaner, potentially more strategic therapeutic window.
